Depressive symptoms linked to rapid kidney function decline
In a study of adults with normal kidney function, those who had frequent depressive symptoms were more likely to later experience a rapid decline in kidney function. The… read more.
In a study of adults with normal kidney function, those who had frequent depressive symptoms were more likely to later experience a rapid decline in kidney function. The… read more.
GlaxoSmithKline plc announced positive headline results from five studies of the Phase III ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor… read more.
University of California – San Diego In mouse models of human disease, immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and… read more.
Bayer announced the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death,… read more.
The European Medicine Agency’s key decision-making committee on human medicines (CHMP), has recommended eight medicines for approval at its June meeting. The Committee recommended granting a conditional marketing authorisation for Abecma… read more.
Diurnal Group plc announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorisation for Efmody (hydrocortisone modified-release hard capsules – development name… read more.
Advicenne announces that the Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Sibnayal (ADV 7103) in the UK, for the treatment of distal renal… read more.
Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication… read more.
AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes… read more.
Article by Bruce Sylvester. Investigative tirzepatide appears to improve glycaemic control and bodyweight in Type 2 diabetes patients, without raising the risk of hypoglycemia. Researchers reported these findings… read more.
Novo Nordisk presented data showing that an investigational 2.0 mg dose of Ozempic (semaglutide) provided statistically significant and superior reductions in blood sugar (HbA1C) compared with Ozempic 1.0… read more.
The European Commission has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.